Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics J. 2014 Apr;14(2):176-81. doi: 10.1038/tpj.2013.12. Epub 2013 Apr 2.

Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.

Author information

1
1] Department of Neuroscience, Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
2
1] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [2] Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
3
1] Department of Neuroscience, Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [3] Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Abstract

Numerous studies have reported on pharmacogenetics of antidepressant response in depression. In contrast, little is known of response predictors in obsessive-compulsive disorder (OCD), a disorder with among the lowest proportion of responders to medication (40-60%). Our study is the largest investigation to date (N=184) of treatment response and side effects to antidepressants in OCD based on metabolizer status for CYP2D6 and CYP2C19. We observed significantly more failed medication trials in CYP2D6 non-extensive compared with extensive metabolizers (P=0.007). CYP2D6 metabolizer status was associated with side effects to venlafaxine (P=0.022). There were nonsignificant trends for association of CYP2D6 metabolizer status with response to fluoxetine (P=0.056) and of CYP2C19 metabolizer status with response to sertraline (P=0.064). Our study is the first to indicate that CYP genes may have a role in antidepressant response in OCD. More research is required for a future clinical application of genetic testing, which could lead to improved treatment outcomes.

PMID:
23545896
DOI:
10.1038/tpj.2013.12
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center